Tunnel infection diagnosed by 18 F-FDG PET/CT scan

Sangeetha, B; Chandra, V. Sarat; Nagula, Praveen; Ram, R; Kumar, VSiva

doi:10.1007/s13730-017-0296-8

Cited by 1 publication

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…tunnel infection and encapsulating peritoneal fibrosis). [1][2][3][4] The concept of 18 F-FDG PET/CT scan is that metabolically active cells absorb the 18 F-FDG tracer via transcellular glucose channels. Intracellular 18 F-FDG then is phosphorylated to FDG-6-Phosphate, which is not further metabolised.…”

Section: Introductionmentioning

confidence: 99%

Is icodextrin use feasible in a peritoneal dialysis patient undergoing 18 F-FDG PET/CT scan?

2022

View full text Add to dashboard Cite

18 F-FDG PET/CT scan is a useful diagnostic tool in patients with neoplasia or inflammatory diseases for further evaluation. Due to interference of glucose with the cellular uptake of the 18 F-FDG tracer via glucose transporter, withhold of any glucose source several hours before imaging is mandatory. This is also the case in peritoneal dialysis patients where glucose-containing peritoneal dialysis fluid cannot be used prior to 18 F-FDG PET/CT scan. Whether the same hold true for icodextrin is not known. We describe two patients with metastatic carcinomas while on peritoneal dialysis on an icodextrin-containing regimen, in whom icodextrin was not discontinued before 18 F-FDG PET/CT scan and where accurate diagnosis of metastatic lesions as well as in one case a simultaneous tunnel infection could be made. Our observation suggests that there is no significant interference of icodextrin with the metabolism of 18 F-FDG and so it is feasible to continue an established icodextrin-containing regimen in peritoneal dialysis patients in case of 18 F-FDG PET/CT scan.

show abstract

Section: Introductionmentioning

confidence: 99%